Simplify Logo

Full-Time

Principal Bioinformatician

Confirmed live in the last 24 hours

Sana Biotechnology

Sana Biotechnology

201-500 employees

Develops engineered cell therapies for diseases

Biotechnology
Healthcare

Compensation Overview

$175k - $205kAnnually

Senior

Cambridge, MA, USA

Category
Bioinformatics
Biology & Biotech
Required Skills
Python
R
Git
SQL
Requirements
  • Advanced degree in Computational Biology, Bioinformatics, or related discipline and 8-10 years of related experience; or an equivalent combination of education and experience
  • Experience with epigenetic preprocessing pipeline and secondary analysis
  • Experience with WGS, WES, and amplicon-sequencing pipeline
  • Competency with R, Python, SQL
  • Familiarity with nextflow
  • Excellent interpersonal, verbal, and written communication skills to effectively communicate results to non-bioinformatic team members; strong organizational and analytical skills; and the ability to work in a highly cooperative team environment as well as independently
  • Knowledge of version control (GitHub, Docker, conda) is a plus
  • Experience with biological data
Responsibilities
  • Maintain preprocessing pipelines for CUT&TAG, CUT&RUN, and genome sequencing data. This requires an extensive working knowledge of linux/unix commands, computer programming languages (R/python) and application of open-source software tools
  • Secondary analyses of processed epigenetics and genome data including identification of high-risk single nucleotide polymorphism, pathway enrichment analysis, functional annotation, transcription factor binding site prediction, putative motif identification, and chromatin accessibility prediction
  • Storage and maintenance (data management) of raw data

Sana Biotechnology develops engineered cells aimed at treating and potentially curing various diseases by addressing their root causes. Their approach involves repairing and controlling genes within cells or replacing damaged or missing cells, which can lead to new types of medicines that improve patient outcomes. The company primarily serves healthcare providers, research institutions, and pharmaceutical companies seeking advanced therapeutic solutions. Unlike many competitors, Sana focuses heavily on research and development of cellular therapies, monetizing their innovations through licensing agreements and partnerships. Their goal is to create effective treatments for a wide range of diseases, enhancing patient care and outcomes.

Company Stage

IPO

Total Funding

$865M

Headquarters

Seattle, Washington

Founded

2018

Growth & Insights
Headcount

6 month growth

0%

1 year growth

-16%

2 year growth

-27%
Simplify Jobs

Simplify's Take

What believers are saying

  • Sana's recent FDA clearance for investigational new drug applications, such as SC262 and SC291, indicates promising progress in their clinical trials.
  • The company's ability to raise significant funds through PIPE offerings and public stock offerings demonstrates strong investor confidence and financial stability.
  • Expansion into key biotech hubs like Cambridge, MA, suggests growth opportunities and access to top-tier talent.

What critics are saying

  • The resignation of key executives like Dr. Douglas Williams could disrupt R&D momentum and strategic direction.
  • High competition in the biotechnology sector, especially in gene and cell therapy, may impact market share and revenue growth.

What makes Sana Biotechnology unique

  • Sana Biotechnology focuses on engineered cells to treat and potentially cure diseases at their genetic and cellular roots, setting it apart from traditional pharmaceutical approaches.
  • Their heavy investment in R&D and partnerships with pharmaceutical companies and research institutions provide a robust pipeline for innovative therapies.
  • Sana's hypoimmune platform, which aims to create cells that can 'hide' from the patient's immune system, is a unique technological advancement in the field.